Careers at Quanterix


Quanterix seeks to improve the healthcare system by providing insight into what takes place in the process from being healthy to becoming ill. Using collaboration with scientists, investors, and advisors, Quanterix has a goal of improving upon the science of precision health.

Product Segments

  • Oncology: Creates new options for the diagnosis, and treatment in cancer research by detecting oncology biomarkers at extremely low levels.
  • Neurology: Offers the ability to detect disease and brain injuries at early stages in order to understand their long-term effects and the disease pathology. By being able to detect low levels of biomarkers, detections of brain injuries and diseases can be significantly improved.
  • Cardiology: Advances the future of heart health by detecting cardiac biomarkers at low levels. By providing insight into small changes, at-risk patients can be identified sooner.
  • Inflammatory: Enables new discoveries to be made into the cause and role of inflammation in health and disease. Measures inflammatory and anti-inflammatory molecules in serum and plasma using highly sensitive techniques.
  • Infectious Disease: Offers crucial insight into the spread and onset of infectious diseases. This type of information is very useful in controlling the spread of disease.


Quanterix was founded in 2007. David R. Walt founded the company after many years of studying chemistry, with a vision of the diagnostics company being the “driving force” in a global industry. Initially Quanterix was a part of Walt’s large intellectual property portfolio, for developing a platform which could measure proteins at a high sensitivity.

Quickly the company was backed by $15 million in funding in 2008. By using a single molecule array (SiMoA), the diagnosis can be 1,000 times more sensitive than the enzyme-linked immunosorbent assay (ELISA) which was the standard form of diagnosis at the time.

In 2010, Quanterix received a lot of attention after a publication was released by Nature Biotechnology. In this publication it was shown that the SiMoA was 1,700 more accurate than the ELISA at spotting the prostate specific antigen. Since then the SiMoA technology has been used to detect and advance research in areas such as oncology, neurology, cardiology, inflammation, and infectious diseases.

The technology is available for purchase from $150,000 to $180,000, or access can be provided through the Quanterix accelerator program. Quanterix uses leading edge technology to provide early detection and insight into a wide range of healthcare issues.

Benefits at Quanterix